A Phase 4 interventional study of IgPro20 in Primary Immunodeficiency, sponsored by CSL Behring. Completed at 12 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.
Sponsored by CSL Behring (part of CSL Limited) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Primary Immunodeficiency Diseases by CSL Limited — none open to participants now, none under way, none of them phase 3. Primary Immunodeficiency Diseases · CSL Limited.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, this one has the largest enrollment of the 13 interventional ones that give a count, is the only one that started in 2017, is one of 4 in phase 4, and was the 13th registered.
211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.
Browse Primary Immunodeficiency Diseases studies →None of the 14 studies in Primary Immunodeficiency Diseases by CSL Limited is open now. The open studies under Primary Immunodeficiency Diseases, anywhere →
Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 49 is above the median of 36 across 125 interventional studies indexed under Primary Immunodeficiency Diseases.
Median enrollment 25 across the 13 interventional studies, 27 across the 1 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Primary Immunodeficiency Diseases by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, parallel-arm, non-randomized study is designed to evaluate safety and tolerability of higher infusion parameters of IgPro20 in subjects with primary immunodeficiency (PID). A total of 45 subjects (including at least 14 [30%] pediatric subjects ≤ 17 years of age and at least 9 [20%] obese subjects with body mass index [BMI] of ≥30 kg/m2) with confirmed PID will be evaluated in the study. The study will include three cohorts of 15 subjects each as follows: i) Pump-Assisted Volume Cohort (weekly infusions), volume per injection site of 25 mL up to 50 mL, ii) Pump Assisted Flow Rate Cohort (weekly infusions), flow rate per injection site of 25 mL/hour up to 100 mL/hour, iii) Manual Push Flow Rate Cohort (2 to 7 infusions per week), flow rate per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute). Each cohort will test 3 infusion parameter levels (4 for the pump-assisted flow rate cohort), repeated at least 4 times over a duration of 12 weeks (16 weeks for the flow rate cohort). After 4 infusion weeks at each level, qualifying subjects (responders) will switch to the next infusion parameter level (eg, from 25 to 50 mL/h). During the study, the weekly dose will remain unchanged (as prescribed by treating physician, usually within 100-200 mg/kg per week range); only the respective infusion parameter under evaluation will change.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pump-Assisted Flow Rate Cohort subjects only
Pump-Assisted Volume Cohort subjects only
Manual Push Flow Rate Cohort subjects only
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
Drug: IgPro20
Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
Drug: IgPro20
Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
Drug: IgPro20
A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
Also known as: Hizentra
Percentage of Responders
A responder is a subject within the Pump-Assisted Cohorts that performs at least 3 out of 4 valid infusions at a certain infusion parameter level (weekly volumes per injection site of 25-50 mL; weekly flow rates per injection site of 25-100 mL/hour). Determination of a responder in the Manual Push Cohort is more complex due to the expected variable frequency of infusions per week (ie, 5-17) for different subjects. A responder within the Manual Push Cohort is a subject that performs a minimum number of valid infusions during 4 weeks corresponding to a certain flow rate level (\[ie, 2-7 times per week\], flow rates per injection site of 30-120 mL/hour). Valid infusions do not need to be consecutive, but each subject needs to adhere to the same schedule (number of infusions per week) throughout the study. An infusion parameter will be considered successful if at least one third (≥ 33%) of the subjects in the corresponding cohort are responders at that infusion parameter level.
Time frame: At the end of 4 weeks for each planned infusion parameter
Rate of Treatment-emergent Adverse Events (TEAEs) Per Infusion
Adverse event rate per infusion = number of adverse events/total number of infusions prior to subject's start date of non-response. Only events are included which start prior to subject's start date of non-response.
Time frame: At the end of 4 weeks for each planned infusion parameter
Rate of Local TEAEs Per Infusion
Local adverse event rate per infusion = number of local adverse events/total number of infusions prior to subject's start date of non-response. Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC (Not Elsewhere Classified)", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.
Time frame: At the end of 4 weeks for each planned infusion parameter
Time to Onset of Local TEAEs
Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.
Time frame: At the end of 4 weeks for each planned infusion parameter
Intensity of Local TEAEs
Mild = A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate = A type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.
Time frame: At the end of 4 weeks for each planned infusion parameter
Duration of Local TEAEs
Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions".
Time frame: At the end of 4 weeks for each planned infusion parameter
Tolerability of Infusions
Tolerability = number of infusions without severe local adverse events / total number of infusions. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.
Time frame: At the end of 4 weeks for each planned infusion parameter
| Milestone | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| Started | 15 | 18 | 16 |
| Completed | 14 | 17 | 14 |
| Not completed | 1 | 1 | 2 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
A responder is a subject within the Pump-Assisted Cohorts that performs at least 3 out of 4 valid infusions at a certain infusion parameter level (weekly volumes per injection site of 25-50 mL; weekly flow rates per injection site of 25-100 mL/hour). Determination of a responder in the Manual Push Cohort is more complex due to the expected variable frequency of infusions per week (ie, 5-17) for different subjects. A responder within the Manual Push Cohort is a subject that performs a minimum number of valid infusions during 4 weeks corresponding to a certain flow rate level (\[ie, 2-7 times per week\], flow rates per injection site of 30-120 mL/hour). Valid infusions do not need to be consecutive, but each subject needs to adhere to the same schedule (number of infusions per week) throughout the study. An infusion parameter will be considered successful if at least one third (≥ 33%) of the subjects in the corresponding cohort are responders at that infusion parameter level.
| percentage of responders | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml | 86.7 | — | — |
| 40 ml | 73.3 | — | — |
| 50 ml | 73.3 | — | — |
| 25 ml/h | — | 77.8 | — |
| 50 ml/h | — | 77.8 | — |
| 75 ml/h | — | 66.7 | — |
| 100 ml/h | — | 61.1 | — |
| 30 ml/h | — | — | 100.0 |
| 60 ml/h | — | — | 100.0 |
| 120 ml/h | — | — | 87.5 |
Adverse event rate per infusion = number of adverse events/total number of infusions prior to subject's start date of non-response. Only events are included which start prior to subject's start date of non-response.
| Number of TEAEs/infusion | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml | 0.183 | — | — |
| 40 ml | 0.188 | — | — |
| 50 ml | 0.023 | — | — |
| 25 ml/h | — | 0.329 | — |
| 50 ml/h | — | 0.255 | — |
| 75 ml/h | — | 0.140 | — |
| 100 ml/h | — | 0.085 | — |
| 30 ml/h | — | — | 0.064 |
| 60 ml/h | — | — | 0.111 |
| 120 ml/h | — | — | 0.081 |
Local adverse event rate per infusion = number of local adverse events/total number of infusions prior to subject's start date of non-response. Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC (Not Elsewhere Classified)", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.
| Number of local TEAEs/infusion | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml | 0.150 | — | — |
| 40 ml | 0.063 | — | — |
| 50 ml | 0.0 | — | — |
| 25 ml/h | — | 0.286 | — |
| 50 ml/h | — | 0.145 | — |
| 75 ml/h | — | 0.040 | — |
| 100 ml/h | — | 0.021 | — |
| 30 ml/h | — | — | 0.027 |
| 60 ml/h | — | — | 0.082 |
| 120 ml/h | — | — | 0.025 |
Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions". Only events are included which start prior to subject's start date of non-response.
| Days | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml | 1.3 ± 2.45 | — | — |
| 40 ml | 0 ± 0.0 | — | — |
| 25 ml/h | — | 1.7 ± 2.94 | — |
| 50 ml/h | — | 0.0 ± 0.04 | — |
| 75 ml/h | — | 0 ± 0.0 | — |
| 100 ml/h | — | 0 ± NA | — |
| 30 ml/h | — | — | 0.2 ± 0.41 |
| 60 ml/h | — | — | 0.3 ± 0.59 |
| 120 ml/h | — | — | 0.2 ± 0.45 |
Mild = A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. Moderate = A type of AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.
| Participants | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml (mild) | 3 | — | — |
| 25 ml (moderate) | 0 | — | — |
| 25 ml (severe) | 0 | — | — |
| 40 ml (mild) | 1 | — | — |
| 40 ml (moderate) | 0 | — | — |
| 40 ml (severe) | 0 | — | — |
| 50 ml (mild) | 0 | — | — |
| 50 ml (moderate) | 0 | — | — |
| 50 ml (severe) | 0 | — | — |
| 25 ml/h (mild) | — | 4 | — |
| 25 ml/h (moderate) | — | 2 | — |
| 25 ml/h (severe) | — | 0 | — |
| 50 ml/h (mild) | — | 3 | — |
| 50 ml/h (moderate) | — | 0 | — |
| 50 ml/h (severe) | — | 0 | — |
| 75 ml/h (mild) | — | 1 | — |
| 75 ml/h (moderate) | — | 0 | — |
| 75 ml/h (severe) | — | 0 | — |
| 100 ml/h (mild) | — | 0 | — |
| 100 ml/h (moderate) | — | 0 | — |
| 100 ml/h (severe) | — | 1 | — |
| 30 ml/h (mild) | — | — | 3 |
| 30 ml/h (moderate) | — | — | 0 |
| 30 ml/h (severe) | — | — | 0 |
| 60 ml/h (mild) | — | — | 4 |
| 60 ml/h (moderate) | — | — | 0 |
| 60 ml/h (severe) | — | — | 0 |
| 120 ml/h (mild) | — | — | 2 |
| 120 ml/h (moderate) | — | — | 0 |
| 120 ml/h (severe) | — | — | 0 |
Local Adverse Events: comprises all events reported within the MedDRA high level terms "administration site reactions NEC", "infusion site reactions", and "injection site reactions".
| Days | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml | 2.2 ± 1.30 | — | — |
| 40 ml | 2.7 ± 2.08 | — | — |
| 25 ml/h | — | 1.2 ± 0.37 | — |
| 50 ml/h | — | 1.6 ± 0.92 | — |
| 75 ml/h | — | 1.0 ± 0.00 | — |
| 100 ml/h | — | 1.0 ± NA | — |
| 30 ml/h | — | — | 2.2 ± 2.86 |
| 60 ml/h | — | — | 5.6 ± 12.91 |
| 120 ml/h | — | — | 3.0 ± 2.12 |
Tolerability = number of infusions without severe local adverse events / total number of infusions. Severe = A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Only events are included which start prior to subject's start date of non-response.
| Ratio | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) |
|---|---|---|---|
| 25 ml | 1.00 | — | — |
| 40 ml | 1.00 | — | — |
| 50 ml | 1.00 | — | — |
| 25 ml/h | — | 1.00 | — |
| 50 ml/h | — | 1.00 | — |
| 75 ml/h | — | 1.00 | — |
| 100 ml/h | — | 0.98 | — |
| 30 ml/h | — | — | 1.00 |
| 60 ml/h | — | — | 1.00 |
| 120 ml/h | — | — | 1.00 |
Collected over Up to 17 weeks per participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 (Pump-assisted Volume) 25 mL | 0/15 (0%) | 0/15 (0%) | 4/15 (26.7%) |
| IgPro20 (Pump-assisted Volume) 40 mL | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| IgPro20 (Pump-assisted Volume) 50 mL | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| IgPro20 (Pump-assisted Flow Rate) 25 mL/h | 0/18 (0%) | 0/18 (0%) | 7/18 (38.9%) |
| IgPro20 (Pump-assisted Flow Rate) 50 mL/h | 0/14 (0%) | 0/14 (0%) | 4/14 (28.6%) |
| IgPro20 (Pump-assisted Flow Rate) 75 mL/h | 0/13 (0%) | 0/13 (0%) | 3/13 (23.1%) |
| IgPro20 (Pump-assisted Flow Rate) 100 mL/h | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| IgPro20 (Manual Push Flow Rate) 30 mL/h | 0/16 (0%) | 0/16 (0%) | 5/16 (31.3%) |
| IgPro20 (Manual Push Flow Rate) 60 mL/h | 0/16 (0%) | 1/16 (6.3%) | 8/16 (50%) |
| IgPro20 (Manual Push Flow Rate) 120 mL/h | 0/14 (0%) | 0/14 (0%) | 7/14 (50%) |
| Event | IgPro20 (Pump-assisted Volume) 25 mL | IgPro20 (Pump-assisted Volume) 40 mL | IgPro20 (Pump-assisted Volume) 50 mL | IgPro20 (Pump-assisted Flow Rate) 25 mL/h | IgPro20 (Pump-assisted Flow Rate) 50 mL/h | IgPro20 (Pump-assisted Flow Rate) 75 mL/h | IgPro20 (Pump-assisted Flow Rate) 100 mL/h | IgPro20 (Manual Push Flow Rate) 30 mL/h | IgPro20 (Manual Push Flow Rate) 60 mL/h | IgPro20 (Manual Push Flow Rate) 120 mL/h |
|---|---|---|---|---|---|---|---|---|---|---|
| suicide attemptPsychiatric disorders | 0/15 | 0/12 | 0/11 | 0/18 | 0/14 | 0/13 | 0/12 | 0/16 | 1/16 | 0/14 |
| Event | IgPro20 (Pump-assisted Volume) 25 mL | IgPro20 (Pump-assisted Volume) 40 mL | IgPro20 (Pump-assisted Volume) 50 mL | IgPro20 (Pump-assisted Flow Rate) 25 mL/h | IgPro20 (Pump-assisted Flow Rate) 50 mL/h | IgPro20 (Pump-assisted Flow Rate) 75 mL/h | IgPro20 (Pump-assisted Flow Rate) 100 mL/h | IgPro20 (Manual Push Flow Rate) 30 mL/h | IgPro20 (Manual Push Flow Rate) 60 mL/h | IgPro20 (Manual Push Flow Rate) 120 mL/h |
|---|---|---|---|---|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 1/15 | 1/12 | 0/11 | 3/18 | 0/14 | 0/13 | 0/12 | 0/16 | 1/16 | 0/14 |
| Injection site painGeneral disorders | 1/15 | 0/12 | 0/11 | 2/18 | 2/14 | 0/13 | 1/12 | 1/16 | 2/16 | 1/14 |
| HeadacheNervous system disorders | 0/15 | 0/12 | 0/11 | 0/18 | 2/14 | 1/13 | 1/12 | 0/16 | 0/16 | 0/14 |
| Upper respiratory tract infectionInfections and infestations | 0/15 | 0/12 | 0/11 | 0/18 | 0/14 | 0/13 | 0/12 | 0/16 | 0/16 | 2/14 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 0/12 | 0/11 | 0/18 | 0/14 | 0/13 | 0/12 | 2/16 | 1/16 | 0/14 |
| NauseaGastrointestinal disorders | 0/15 | 0/12 | 0/11 | 0/18 | 0/14 | 0/13 | 0/12 | 2/16 | 0/16 | 0/14 |
| Injection site swellingGeneral disorders | 1/15 | 0/12 | 0/11 | 2/18 | 0/14 | 0/13 | 0/12 | 1/16 | 1/16 | 1/14 |
| Injection site pruritusGeneral disorders | 0/15 | 0/12 | 0/11 | 2/18 | 1/14 | 0/13 | 0/12 | 0/16 | 1/16 | 0/14 |
| Respiratory tract infection viralInfections and infestations | 0/15 | 0/12 | 1/11 | 0/18 | 0/14 | 0/13 | 0/12 | 0/16 | 0/16 | 0/14 |
| Hot flushVascular disorders | 0/15 | 1/12 | 0/11 | 0/18 | 0/14 | 0/13 | 0/12 | 0/16 | 0/16 | 0/14 |
| Age, Categorical(Participants) | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 11 | 1 | 12 |
| Between 18 and 65 years | 14 | 5 | 14 | 33 |
| >=65 years | 1 | 2 | 1 | 4 |
| Age, Continuous(years) | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) | Total |
|---|---|---|---|---|
| Mean | 49.1 ± 14.18 | 26.7 ± 24.52 | 47.9 ± 13.28 | 40.5 ± 20.97 |
| Sex: Female, Male(Participants) | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) | Total |
|---|---|---|---|---|
| Female | 9 | 10 | 10 | 29 |
| Male | 6 | 8 | 6 | 20 |
| Race (NIH/OMB)(Participants) | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 2 |
| White | 14 | 16 | 12 | 42 |
| More than one race | 1 | 0 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(participants) | IgPro20 (Pump-Assisted Volume Cohort) | IgPro20 (Pump Assisted Flow Rate Cohort) | IgPro20 (Manual Push Flow Rate Cohort) | Total |
|---|---|---|---|---|
| Canada | 3 | 0 | 6 | 9 |
| United States | 12 | 18 | 10 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Dec 2018, 22 months.
Results were first posted in Jan 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hizentra
Primary Immunodeficiency Diseases →